Clinical Trial Update: Studying Complement Inhibition in Early, Newly Developing Septic Organ Dysfunction [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a complement inhibitor (vilobelimab/IFX-1) for early septic organ dysfunction has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sepsis
• Septic Shock

Drugs mentioned

• Vilobelimab (vilobelimab)

Snippet

Sponsor: InflaRx GmbH | Conditions: Severe Sepsis, Septic Shock | Phase 2 | Status: COMPLETED